TY  - JOUR
AU  - Mai, Elias K
AU  - Benner, Axel
AU  - Bertsch, Uta
AU  - Brossart, Peter
AU  - Hänel, Annette
AU  - Kunzmann, Volker
AU  - Naumann, Ralph
AU  - Neben, Kai
AU  - Egerer, Gerlinde
AU  - Ho, Anthony D
AU  - Hillengass, Jens
AU  - Raab, Marc S
AU  - Neubauer, Andreas
AU  - Peyn, Astrid
AU  - Ko, Yon-Dschun
AU  - Peter, Norma
AU  - Scheid, Christof
AU  - Goldschmidt, Hartmut
TI  - Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
JO  - British journal of haematology
VL  - 173
IS  - 5
SN  - 0007-1048
CY  - Oxford [u.a.]
PB  - Wiley-Blackwell55962
M1  - DKFZ-2017-05110
SP  - 731 - 741
PY  - 2016
AB  - The prospective, randomized phase III trial GMMG-HD2 aimed at demonstrating non-inferiority of single (Arm A) versus tandem (Arm B) high-dose melphalan followed by autologous transplantation (HDM/ASCT) with regard to 2-year event-free survival (EFS) in newly-diagnosed multiple myeloma (MM) and included 358 evaluable patients [Intention-to-treat population, (ITT), single/tandem HDM/ASCT: n = 177/181]. After a median follow-up of more than 11 years, non-inferiority of single versus tandem HDM/ASCT was demonstrated using the planned non-inferiority threshold of 15
KW  - Myeloablative Agonists (NLM Chemicals)
KW  - Melphalan (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:26990892
DO  - DOI:10.1111/bjh.13994
UR  - https://inrepo02.dkfz.de/record/129105
ER  -